Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
Birgitte Bentz DamholtSarah Louise DombernowskyMette Dahl BendtsenCharlotte BisgaardMichael Højby RasmussenPublished in: Clinical pharmacokinetics (2021)
NCT03186495 (kidney impairment trial, registered 12 June 2017); NCT03212131 (hepatic impairment trial, registered 30 June 2017).